Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Bracco Diagnostics Highlights Advancement in Diagnostic Imaging Portfolio

By Medimaging International staff writers
Posted on 29 Nov 2017
Print article
Image: The Bracco Group is celebrating its 90th anniversary and the celebration of the 25th anniversary of its launch of the first macrocyclic gadolinium MRI contrast agent approved in the U.S (Photo courtesy of the Bracco Group).
Image: The Bracco Group is celebrating its 90th anniversary and the celebration of the 25th anniversary of its launch of the first macrocyclic gadolinium MRI contrast agent approved in the U.S (Photo courtesy of the Bracco Group).
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A. (Milan, Italy), a diagnostic imaging company, highlighted the breadth, depth and ongoing advancement of its diagnostic imaging solutions and services portfolio at the Radiological Society of North America (RSNA) Annual Meeting.

Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions for all key modalities: X-ray imaging (including Computed Tomography-CT, interventional radiology, and cardiac catheterization), magnetic resonance imaging (MRI), contrast enhanced ultrasound (CEUS), and nuclear medicine through radioactive tracers. The company also offers a range of medical devices and advanced administration systems for its contrast imaging products.

At the RSNA 2017 held in Chicago, IL, Nov. 26 - Dec. 1, 2017, Bracco Imaging provided a glimpse of its major achievements which impacted the company this year, such as the Bracco Group’s 90th anniversary and the celebration of the 25th anniversary of its launch of the first macrocyclic gadolinium MRI contrast agent approved in the U.S. The company also highlighted the FDA approval for its CEUS agent for use in ultrasonography of the urinary tract (voiding ultrasonography) for the evaluation of suspected or known vesicoureteral reflux in pediatric patients, and the launch of its best-in-class contrast media injector technology through its SmartInjectCT solution.

Other major achievements for Bracco included the FDA approval for four additional barium-based products, the introduction of its new automated, software-controlled insufflator to inflate the colon with CO2, and the launch of the first-ever patient and referring physician website as a resource to learn more about colorectal cancer screening with CTC and for patients to find a radiology clinic near them.

"We've remained relentless in our pursuit to consistently deliver diagnostic imaging solutions and services that focus on efficacy, safety, quality and cost effectiveness and are aligned with the distinct needs of patients and physicians," said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. "These milestones, as well as our successful track record of bringing innovative products and solutions to the diagnostic imaging market, demonstrate our unwavering dedication to this end."

"These achievements affirm our continued commitment to help healthcare professionals provide optimal and high quality patient care," said Alberto Spinazzi, MD, Senior Vice President, Head of Global Medical and Regulatory Affairs, Bracco Group. "Besides, we are proud to work collaboratively with the US FDA and many institutions across the country, to improve the safe and effective use of our imaging agents."


Print article
Radcal

Channels

Copyright © 2000-2017 Globetech Media. All rights reserved.